by Market Overview:
Relapsed or refractory diffuse large B-cell lymphoma (RR DLBCL) is an aggressive type of non-Hodgkin’s lymphoma. It is known to be difficult to treat, especially in patients whose disease has returned after initial therapy or who did not respond to initial therapy. Targeted therapies play an important role in treatment of RR DLBCL, as they attack cancer cells more precisely with fewer side effects than other therapies.
Market key trends:
Increasing adoption of targeted therapies is expected to drive growth of the relapsed or refractory diffuse large B cell lymphoma market over the forecast period. Targeted therapies such as monoclonal antibodies and antibody-drug conjugates act with more precision than conventional chemotherapy. For example, the anti-CD19 antibody innovimab by MorphoSys has shown high response rates and manageable safety profile in patients with RR DLBCL. Advancements in development of novel targeted therapies offer hope for better outcomes in patients with Relapsed Or Refractory Diffuse Large B Cell Lymphoma Market.
Porter’s Analysis
Threat of new entrants: Low barriers to entry in terms of technology and patents. However, the market is dominated by a few large players which makes it difficult for new players to enter.
Bargaining power of buyers: Individual patients have low bargaining power but large group purchasing hospitals and insurance companies have moderate bargaining power to negotiate pricing.
Bargaining power of suppliers: Suppliers of raw materials including active pharmaceutical ingredients have moderate bargaining power as they are specialty ingredients and suppliers.
Threat of new substitutes: Moderate threat from new substitute therapies and drug combinations being explored for treatment.
Competitive rivalry: High as major players invest heavily in R&D and focus on clinical trials to develop novel therapies and gain market share.
SWOT Analysis
Strengths: Growing patient pool, rising healthcare spending, significant unmet medical needs.
Weaknesses: High R&D costs, long product development cycles, patent cliffs of major drugs.
Opportunities: Emerging economies with large patient populations, combinations with other targeted therapies, biomarker developments for better patient selection.
Threats: Pricing pressures, fast approval of biosimilars, safety concerns over long term use.
Key Takeaways
The global relapsed or refractory diffuse large B cell lymphoma market is expected to witness high growth, exhibiting a CAGR of 4.3% over the forecast period, due to increasing investment in R&D of novel therapies. The United States dominates the market currently due to presence of major players, higher healthcare spending and approvals of novel therapies. The Asia Pacific region is expected to grow at the fastest pace due to rising healthcare infrastructure, growing disposable income and increasing patient awareness.
Key players operating in the relapsed or refractory diffuse large B cell lymphoma market are MorphoSys U.S. Inc., Bristol-Myers Squibb Company, Karyopharm Therapeutics, Hoffmann-La Roche AG, Merck & Co., Inc., Gilead Sciences, Inc., Novartis AG, Regeneron Pharmaceuticals, Cellular Biomedicine Group Inc., Genmab A/S, Incyte, AbbVie Inc., Janssen Biotech, Inc., Pfizer Inc., IMV Inc., Overland Pharmaceuticals (CY) Inc., ADC Therapeutics SA, Eagle Pharmaceuticals, Inc., and Adaptive Biotechnologies Corporation.
Note:
- Source: Coherent Market Insights, Public sources, Desk research
- We have leveraged AI tools to mine information and compile it
